Replimune Group Net Income
| REPL Stock | USD 7.39 0.03 0.41% |
As of the 30th of January, Replimune holds the Coefficient Of Variation of (1,823), variance of 13.25, and Risk Adjusted Performance of (0.03). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Replimune, as well as the relationship between them. Please check Replimune Group market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Replimune Group is priced some-what accurately, providing market reflects its current price of 7.39 per share. Given that Replimune has information ratio of (0.07), we recommend you to check out Replimune Group's recent market performance to make sure the company can sustain itself at a future point.
Replimune's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Replimune's valuation are provided below:There are over one hundred nineteen available trending fundamental ratios for Replimune Group, which can be analyzed over time and compared to other ratios. We recommend to check out Replimune's recent fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 568.6 M this year. Enterprise Value is expected to rise to about 527.2 M this year This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -222.6 M | -211.4 M | |
| Net Loss | -106.2 M | -100.9 M | |
| Net Loss | -222.6 M | -211.4 M | |
| Net Loss | (3.53) | (3.71) | |
| Net Income Per E B T | 0.90 | 0.79 |
Replimune | Net Income | Build AI portfolio with Replimune Stock |
Historical Net Income data for Replimune serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Replimune Group represents a compelling investment opportunity.
Latest Replimune's Net Income Growth Pattern
Below is the plot of the Net Income of Replimune Group over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Replimune Group financial statement analysis. It represents the amount of money remaining after all of Replimune Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Replimune's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Replimune's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (247.3 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Replimune Net Income Regression Statistics
| Arithmetic Mean | (83,963,308) | |
| Coefficient Of Variation | (110.40) | |
| Mean Deviation | 80,663,222 | |
| Median | (30,834,000) | |
| Standard Deviation | 92,698,900 | |
| Sample Variance | 8593.1T | |
| Range | 239.6M | |
| R-Value | (0.91) | |
| Mean Square Error | 1635.9T | |
| R-Squared | 0.82 | |
| Slope | (16,638,484) | |
| Total Sum of Squares | 137489.4T |
Replimune Net Income History
Other Fundumenentals of Replimune Group
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Replimune Net Income component correlations
Replimune Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Replimune is extremely important. It helps to project a fair market value of Replimune Stock properly, considering its historical fundamentals such as Net Income. Since Replimune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Replimune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Replimune's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Replimune 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Replimune's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Replimune.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Replimune on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Replimune Group or generate 0.0% return on investment in Replimune over 90 days. Replimune is related to or competes with Ginkgo Bioworks, MBX Biosciences, Iovance Biotherapeutics, ArriVent BioPharma, MeiraGTx Holdings, Prime Medicine, and Valneva SE. Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer More
Replimune Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Replimune's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Replimune Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 20.44 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 5.56 |
Replimune Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Replimune's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Replimune's standard deviation. In reality, there are many statistical measures that can use Replimune historical prices to predict the future Replimune's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.47) | |||
| Treynor Ratio | (0.25) |
Replimune January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 2.73 | |||
| Coefficient Of Variation | (1,823) | |||
| Standard Deviation | 3.64 | |||
| Variance | 13.25 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.47) | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 20.44 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 5.56 | |||
| Skewness | 0.5909 | |||
| Kurtosis | 1.34 |
Replimune Group Backtested Returns
Replimune Group maintains Sharpe Ratio (i.e., Efficiency) of -0.1, which implies the firm had a -0.1 % return per unit of risk over the last 3 months. Replimune Group exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Replimune's Variance of 13.25, coefficient of variation of (1,823), and Risk Adjusted Performance of (0.03) to confirm the risk estimate we provide. The company holds a Beta of 0.84, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Replimune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Replimune is expected to be smaller as well. At this point, Replimune Group has a negative expected return of -0.33%. Please make sure to check Replimune's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Replimune Group performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.85 |
Excellent reverse predictability
Replimune Group has excellent reverse predictability. Overlapping area represents the amount of predictability between Replimune time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Replimune Group price movement. The serial correlation of -0.85 indicates that around 85.0% of current Replimune price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.85 | |
| Spearman Rank Test | -0.77 | |
| Residual Average | 0.0 | |
| Price Variance | 1.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Replimune Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Replimune Group reported net income of (247.3 Million). This is 172.46% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 143.31% higher than that of the company.
Replimune Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Replimune's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics of similar companies.Replimune is currently under evaluation in net income category among its peers.
Replimune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Replimune from analyzing Replimune's financial statements. These drivers represent accounts that assess Replimune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Replimune's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.4B | 886.6M | 1.0B | 514.6M | 463.1M | 568.6M | |
| Enterprise Value | 1.3B | 813.5M | 942.2M | 516.0M | 464.4M | 527.2M |
Replimune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Replimune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Replimune's managers, analysts, and investors.Environmental | Governance | Social |
Replimune Institutional Holders
Institutional Holdings refers to the ownership stake in Replimune that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Replimune's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Replimune's value.| Shares | Marshall Wace Asset Management Ltd | 2025-06-30 | 1.9 M | Sofinnova Ventures | 2025-06-30 | 1.8 M | Geode Capital Management, Llc | 2025-06-30 | 1.6 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.2 M | Goldman Sachs Group Inc | 2025-06-30 | 1.1 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 983.8 K | Wellington Management Company Llp | 2025-06-30 | 944.5 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 921.7 K | Rosalind Advisors, Inc. | 2025-06-30 | 900 K | Baker Bros Advisors Lp | 2025-06-30 | 11 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 10.8 M |
Replimune Fundamentals
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 330.81 M | ||||
| Shares Outstanding | 78.44 M | ||||
| Shares Owned By Insiders | 2.32 % | ||||
| Shares Owned By Institutions | 97.68 % | ||||
| Number Of Shares Shorted | 14.4 M | ||||
| Price To Book | 2.20 X | ||||
| EBITDA | (253.92 M) | ||||
| Net Income | (247.3 M) | ||||
| Cash And Equivalents | 395.08 M | ||||
| Cash Per Share | 8.01 X | ||||
| Total Debt | 76.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 19.79 X | ||||
| Book Value Per Share | 3.36 X | ||||
| Cash Flow From Operations | (192.25 M) | ||||
| Short Ratio | 11.52 X | ||||
| Earnings Per Share | (3.47) X | ||||
| Target Price | 12.57 | ||||
| Number Of Employees | 479 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 579.7 M | ||||
| Total Asset | 551.33 M | ||||
| Retained Earnings | (948.58 M) | ||||
| Working Capital | 433.52 M | ||||
| Net Asset | 551.33 M |
About Replimune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Replimune Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.